Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, Huuhtanen J, Suvela M, Parsons A, Holopainen A, Partanen A, Kuusisto MEL, Koskela S, Räty R, Itälä-Remes M, Västrik I, Dufva O, Siitonen S, Porkka K, Wennerberg K, Heckman CA, Ettala P, Pyörälä M, Rimpiläinen J, Siitonen T, Kontro M. Kuusanmäki H, et al. Among authors: suvela m. Haematologica. 2023 Jul 1;108(7):1768-1781. doi: 10.3324/haematol.2022.281692. Haematologica. 2023. PMID: 36519325 Free PMC article.
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Pemovska T, et al. Among authors: suvela m. Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20. Cancer Discov. 2013. PMID: 24056683
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. Karjalainen R, et al. Among authors: suvela m. Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15. Blood. 2017. PMID: 28619982 Free article.
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanmäki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA. Majumder MM, et al. Among authors: suvela m. Oncotarget. 2017 May 5;8(34):56338-56350. doi: 10.18632/oncotarget.17630. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915594 Free PMC article.
S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.
Liu M, Wang Y, Miettinen JJ, Kumari R, Majumder MM, Tierney C, Bazou D, Parsons A, Suvela M, Lievonen J, Silvennoinen R, Anttila P, Dowling P, O'Gorman P, Tang J, Heckman CA. Liu M, et al. Among authors: suvela m. Front Cell Dev Biol. 2021 Aug 16;9:723016. doi: 10.3389/fcell.2021.723016. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34485305 Free PMC article.
The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death.
Flanagan K, Kumari R, Miettinen JJ, Haney SL, Varney ML, Williams JT, Majumder MM, Suvela M, Slipicevic A, Lehmann F, Nupponen NN, Holstein SA, Heckman CA. Flanagan K, et al. Among authors: suvela m. Hemasphere. 2022 Feb 25;6(3):e687. doi: 10.1097/HS9.0000000000000687. eCollection 2022 Mar. Hemasphere. 2022. PMID: 35243210 Free PMC article.
Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
Kytölä S, Vänttinen IM, Ruokoranta T, Partanen A, Holopainen A, Saad J, Kuusisto MEL, Koskela S, Räty RK, Itälä-Remes M, Västrik I, Suvela M, Parsons AO, Porkka K, Wennerberg K, Heckman CA, Jalkanen T, Huttunen T, Ettala P MD, Rimpiläinen J, Siitonen T, Pyörälä M, Kuusanmäki H, Kontro M. Kytölä S, et al. Among authors: suvela m. Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968. Online ahead of print. Blood. 2024. PMID: 39357056
No evidence for shared etiology in two demyelinative disorders, MS and PLOSL.
Sulonen AM, Kallio SP, Ellonen P, Suvela M, Elovaara I, Koivisto K, Pirttilä T, Reunanen M, Tienari PJ, Palotie A, Peltonen L, Saarela J. Sulonen AM, et al. Among authors: suvela m. J Neuroimmunol. 2009 Jan 3;206(1-2):86-90. doi: 10.1016/j.jneuroim.2008.10.005. Epub 2008 Nov 18. J Neuroimmunol. 2009. PMID: 19019460 Free PMC article.
MYO9B polymorphisms in multiple sclerosis.
Kemppinen A, Suvela M, Tienari PJ, Elovaara I, Koivisto K, Pirttilä T, Reunanen M, Rautakorpi I, Hillert J, Lundmark F, Oturai A, Ryder L, Harbo HF, Celius EG, Palotie A, Daly M, Peltonen L, Saarela J. Kemppinen A, et al. Among authors: suvela m. Eur J Hum Genet. 2009 Jun;17(6):840-3. doi: 10.1038/ejhg.2008.251. Epub 2009 Jan 14. Eur J Hum Genet. 2009. PMID: 19142207 Free PMC article.
51 results